Trial Profile
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Criterium
- 02 Apr 2018 Status changed from recruiting to discontinued.
- 16 Oct 2017 Planned End Date changed from 1 Aug 2017 to 30 Mar 2018.
- 16 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Dec 2017.